{"schema_version":"1.0","type":"article","title":"J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.md","lang":"en","date":"2026-08-09","publish_at":"2026-08-09T08:00:00+08:00","updated_at":"2026-08-09","category":"商業分析系列","topic":"商業分析系列","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","Psoriasis","IL-23R","Oral Peptide","Drug Commercialization"],"summary":"ICOTYDE logged more than 18,000 prescriptions in its first full quarter. The oral IL-23R peptide has earned entry into the high-efficacy psoriasis market, but durable value still depends on paid fills, persistence, payer quality, safety, and additional indications.","key_points":[],"facts":[],"sections":["01 | One Pill a Day: How Did J&J Get a Peptide into the Body?","02 | Eighteen Thousand Prescriptions Ignited the Launch, but Payment Quality Still Needs Testing","03 | An Oral Drug Finally Has an Efficacy Case","04 | Once Daily Still Has to Survive the Real World","05 | A $5 Billion Ambition Requires Multiple Indications","06 | One Successful Product Does Not Yet Validate an Entire Platform","07 | What Should Taiwan-Based Readers Watch Next?","The Bottom Line","Primary Sources","Disclaimer"],"references":[{"title":"[FDA ICOTYDE label]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf"},{"title":"[FDA multidisciplinary review]","source":"","date":"","url":"https://www.fda.gov/media/192646/download"},{"title":"[J&J FDA approval release]","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide"},{"title":"[J&J 2025 PASI 90 maintenance results]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2025/Icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis/default.aspx"},{"title":"[J&J one-year results]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/ICOTYDE-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis/default.aspx"},{"title":"[J&J second-quarter 2026 results]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx"},{"title":"[J&J second-quarter 2026 earnings call transcript]","source":"","date":"","url":"https://s203.q4cdn.com/636242992/files/doc_financials/2026/q2/JNJ-USQ_Transcript_2026-07-15.pdf"},{"title":"[J&J development pipeline]","source":"","date":"","url":"https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx"}],"images":[{"alt":"ICOTYDE enters the high-efficacy oral psoriasis market","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-01.png"},{"alt":"Prescription volume, patient counts, prescriber reach, and insurance coverage are demand signals, not a complete revenue answer","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-02.png"},{"alt":"The one-year maintenance result must be read using the correct responder denominator","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-03.png"},{"alt":"The commercial follow-up for ICOTYDE centers on paid prescriptions, refill persistence, access quality, and long-term outcomes","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-09）。J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?。https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-09-icotyde-oral-il23r-launch.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}